Determinação das melhores condições de hidrólise física com ultrassom de potência em resíduos de amendoim

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Aplicação de biofungicidas no controle do fungo Aspergillus flavus L. em amendoim (Arachis hypogaea)

Pós-graduação em Engenharia e Ciência de Alimentos - IBILCE

Metodologias de pesquisa e avaliação da resistência de genótipos de amendoim a Spodoptera albula (walker, 1857) (Lepidoptera: Noctuidae)

Pós-graduação em Agronomia (Entomologia Agrícola) - FCAV

Não preferência para alimentação e antibiose em cultivares de amendoim a Stegasta bosquella (Chambers) (Lepidoptera: Gelechiidae)

This work aimed to evaluate the attractiveness, non-preference for feeding and antibiosis in straight and runner growth habit peanut cultivars to Stegasta bosquella (Chambers). Eight cultivars were evaluated, four of straight growth habit (IAC Tatu, IAC 22, IAC 8112 and IAC 5) and four of runner growth habit (IAC Runner 886, IAC 147, IAC 125 and IAC 503). Free-choice and no-choice feeding tests were performed, using pairs of overlapped leaf discs with 1.0 cm diameter, which were placed in Petri dishes where third instar larvae of S. bosquella were released. The attractiveness to the larvae was assessed in predetermined times, in addition to the dry mass consumed. In the antibiosis assay, the biological parameters were evaluated: period and viability of larvae, pre-pupae, pupae, and total, weight of larvae and pupae, sex ratio and longevity. None of the runner growth habit cultivars exhibited non-preference for feeding-type resistance. Among the straight growth habit cultivars, IAC 5 and IAC 22 were the least attractive and consumed in the free-choice feeding test, and IAC 5 and IAC 8112 were the least attractive in the no-choice test. The runner growth habit cultivars IAC 147 and IAC Runner 886 affected the larval survival of S. bosquella, exhibiting antibiosis-type resistance. For the straight growth habit cultivars, IAC 22 and IAC 8112 affected the larval viability, presenting antibiosis-type resistance. The straight and runner growth habit cultivars did not influence the biological parameters of weight of pupae, sex ratio and longevity of S. bosquella.

Tecnologia para produção de extrato aquoso de amendoim

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Bürjerwehr, Du bist bejlückt! Dein Jesetz ist ausjeflickt! Hat nen neuen Schwanz un Kragen! Will nich Ener Bravo sagen? Eine Rede, jehalten von den Bürjerwehr-Esel: Meine Herren! "Ick wollte mich man erlauben zu bemerken", pflegte der vereinigte Landtag zu sagen ...

Welsch (Projektbearbeiter): Satirische Kommentierung der Verabschiedung des Bürgerwehrgesetzes durch die Preußische Nationalversammlung. Hintergrund: Der Linken war es nicht gelungen, "Landwehr und stehendes Heer in einer allgemeinen Volksbewaffnung aufgehen zu lassen", außerdem "verlor sie durch Auflösung der fliegenden Korps der Studenten, Künstler, Arbeiter und Handwerksgesellen eine ihrer wichtigsten Stützen". [Nitschke 1995, 131]

Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial.

BACKGROUND Anticoagulation is required during transcatheter aortic valve replacement (TAVR) procedures. Although an optimal regimen has not been determined, heparin is mainly used. Direct thrombin inhibition with bivalirudin may be an effective alternative to heparin as the procedural anticoagulant agent in this setting. OBJECTIVES The goal of this study was to determine whether bivalirudin offers an alternative to heparin as the procedural anticoagulant agent in patients undergoing TAVR. METHODS A total of 802 patients with aortic stenosis were randomized to undergo transfemoral TAVR with bivalirudin versus unfractionated heparin during the procedure. The 2 primary endpoints were major bleeding within 48 h or before hospital discharge (whichever occurred first) and 30-day net adverse clinical events, defined as the combination of major adverse cardiovascular events (all-cause mortality, myocardial infarction, or stroke) and major bleeding. RESULTS Anticoagulation with bivalirudin versus heparin did not meet superiority because it did not result in significantly lower rates of major bleeding at 48 h (6.9% vs. 9.0%; relative risk: 0.77; 95% confidence interval [CI]: 0.48 to 1.23; p = 0.27) or net adverse cardiovascular events at 30 days (14.4% vs. 16.1%; relative risk: 0.89; 95% CI: 0.64 to 1.24; risk difference: -1.72; 95% CI: -6.70 to 3.25; p = 0.50); regarding the latter, the prespecified noninferiority hypothesis was met (pnoninferiority < 0.01). Rates of major adverse cardiovascular events at 48 h were not significantly different (3.5% vs. 4.8%; relative risk: 0.73; 95% CI: 0.37 to 1.43; p = 0.35). At 48 h, the bivalirudin group had significantly fewer myocardial infarctions but more acute kidney injury events than the heparin group; at 30 days, these differences were no longer significant. CONCLUSIONS In this randomized trial of TAVR procedural pharmacotherapy, bivalirudin did not reduce rates of major bleeding at 48 h or net adverse cardiovascular events within 30 days compared with heparin. Although superiority was not shown, the noninferiority hypothesis was met with respect to the latter factor. Given the lower cost, heparin should remain the standard of care, and bivalirudin can be an alternative anticoagulant option in patients unable to receive heparin in TAVR. (International, Multi-center, Open-label, Randomized Controlled Trial in Patients Undergoing TAVR to Determine the Treatment Effect [Both Safety and Efficacy] of Using Bivalirudin Instead of UFH [BRAVO-2/3]; NCT01651780).

Bravo! Auch ein Wort am rechten Ort! Von einem Privatmanne! Diesen schönen Zuruf vernahm ich den 18. Mai in unserer Residenz ...

Welsch (Projektbearbeiter): Dank an die Kämpfer für die Freiheit, dargebracht von einem Vertreter der "gemeine[n] Leute". Äußerung der Erwartung einer glücklichen Zukunft nach den Ereignissen des 28. Juni 1848 (Gründung des 'Ersten Allgemeinen Arbeitervereins' in Wien)

¡Bravo, Óscar, bravo!

Artículo publicado en el periódico El Mundo el 7 de diciembre de 2012.